Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4439 Target Snapshot

TGF-beta receptor type-1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
3,732Compounds
529Assays
7Approved Drugs
4,757.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

TGF-beta receptor type-1 shows clinical signal disease relevance led by myelodysplastic syndrome. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P36897. Start with myelodysplastic syndrome, then reuse UniProt P36897 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with myelodysplastic syndrome, then reuse UniProt P36897 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 2 linked drugs
Open source guide
Disease program
myelodysplastic syndrome

TGF-beta receptor type-1 shows clinical signal disease relevance led by myelodysplastic syndrome. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with myelodysplastic syndrome because it currently carries clinical signal support. Linked drugs include GALUNISERTIB, VACTOSERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats TGF-beta receptor type-1 as ChEMBL target CHEMBL4439, mapped to UniProt P36897. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
TGF-beta receptor type-1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4439
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P36897
TGF-beta receptor type-1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether TGF-beta receptor type-1 is the right protein anchor across sources, using UniProt P36897 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why myelodysplastic syndrome is currently framed as clinical signal support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameTGF-beta receptor type-1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP36897
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTGF-beta receptor type-1
UniProt AccessionP36897
Component TypeProtein
Sequence Length503 aa

TGF-beta receptor type-1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as TGF-beta receptor type-1, mapped to UniProt P36897. Sequence length is 503 aa.

Mapped IDP36897
Review nameTGF-beta receptor type-1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

TGF-beta receptor type-1 shows clinical signal disease relevance led by myelodysplastic syndrome. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II
myelodysplastic syndrome
2 linked drugs · 2 direct · 2 efficacy
Linked drugGALUNISERTIB
Linked drugVACTOSERTIB
Clinical signal Phase II
gastric cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugVACTOSERTIB
Clinical signal Phase II
glioblastoma multiforme
1 linked drug · 1 direct · 1 efficacy
Linked drugGALUNISERTIB
Clinical signal Phase II
hepatocellular carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugGALUNISERTIB
Clinical signal Phase II
myeloproliferative disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugVACTOSERTIB
Clinical signal Phase II
nasopharyngeal carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugGALUNISERTIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with myelodysplastic syndrome because it currently carries clinical signal support. Linked drugs include GALUNISERTIB, VACTOSERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasemyelodysplastic syndrome
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

7
Approved
5
Phase III
13
Phase II
7
Phase I
Assay Mix

Activity Type Distribution

IC504,072.0
KI64.0
EC50225.0
KD396.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4209835 9.85 Ki 0.14 Preclinical
CHEMBL4210246 9.85 Ki 0.14 Preclinical
CHEMBL4209583 9.82 Ki 0.15 Preclinical
CHEMBL5962152 9.72 IC50 0.19 Preclinical
CHEMBL4217699 9.66 Ki 0.22 Preclinical
CHEMBL5776223 9.6 IC50 0.25 Preclinical
CHEMBL5919249 9.6 IC50 0.25 Preclinical
CHEMBL5864462 9.6 IC50 0.25 Preclinical
CHEMBL5769608 9.6 IC50 0.25 Preclinical
CHEMBL6011920 9.59 IC50 0.26 Preclinical
Distribution

pChEMBL Value Distribution

254
5.0
268
5.5
329
6.0
465
6.5
700
7.0
693
7.5
569
8.0
412
8.5
244
9.0
17
9.5
pChEMBL
Approved Drugs

Approved Drugs

MOMELOTINIB
CHEMBL1078178
Approved 2023
Properties Compare Identifier
CRIZOTINIB
CHEMBL601719
Approved 2011
Properties Compare Identifier
DASATINIB
CHEMBL5416410
Approved 2006
Properties Compare Identifier
Assay Landscape

Assay Landscape

529
Total Assays
2,820
Tested Compounds
3
Assay Types
Binding — 504 assays, 2,820 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 297 1,896 7.5
cell-based format 149 701 7.1
assay format 47 198 6.7
subcellular format 10 24 6.3
tissue-based format 1 1 9.1
Functional — 13 assays, 89 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 10 46 6.9
assay format 2 43 6.8
organism-based format 1 0 —
ADME — 12 assays, 139 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 5 60 6.6
single protein format 5 34 6.0
assay format 2 45 7.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine